Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab in Recurrent Glioblastoma
NCT06097975Phase 1Active, not recruiting
- Sponsor
- UZ Brussel
- Start
- Mar 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in glioblastoma (GBM), sponsored by UZ Brussel. Primary endpoint: Safety and Feasibility of the proposed investigational (neo-)adjuvant treatment regimen at 1 year. Started Mar 2024; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06097975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097975.